Buprenorphine Transdermal System for Opioid Therapy in Patients with Chronic Low Back Pain
OBJECTIVE: The present randomized, double-blinded, crossover study compared the efficacy and safety of a seven-day buprenorphine transdermal system (BTDS) and placebo in patients with low back pain of moderate or greater severity for at least six weeks.
Main Authors: | Allan Gordon, Saifudin Rashiq, Dwight E Moulin, Alexander J Clark, André D Beaulieu, John Eisenhoffer, Paula S Piraino, Patricia Quigley, Zoltan Harsanyi, Andrew C Darke |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | Pain Research and Management |
Online Access: | http://dx.doi.org/10.1155/2010/216725 |
Similar Items
-
Transdermal buprenorphine for pain management in children
by: Giorgio Attinà, et al.
Published: (2021-09-01) -
Management of chronic pain in the elderly: focus on transdermal buprenorphine
by: Nalini Vadivelu, et al.
Published: (2008-09-01) -
Transdermal buprenorphine for acute postoperative pain: a systematic review
by: Felipe Chiodini Machado, et al.
Published: (2020-07-01) -
Transdermal Buprenorphine Patches for Postoperative Pain Control in Abdominal Surgery
by: Santosh Kumar, et al.
Published: (2016-06-01) -
Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system
by: Silverman S, et al.
Published: (2017-05-01)